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Antiplatelet therapy is used widely with proven beneﬁt for the
primary prevention of cardiovascular disease as well as for the
prevention of further ischemic cardiovascular events in patients with
proven coronary artery disease (CAD) and in those with a history of
acute coronary syndrome (ACS). The limitations of conventional
antiplatelet therapy with aspirin, clopidogrel, or prasugrel, as well as
the fact that rates of recurrent ischemic events still remain high with
use of these agents, underscore the need to investigate alternative
molecules that may be effective in further reducing the occurrence of
events without increasing the risk of bleeding. The armamentarium
of antiplatelet therapy has been further enriched by ticagrelor,
cangrelor, vorapaxar, prasugrel and atopaxar. Ticagrelor was ap-
proved in 2011 by the European Medicines Agency swiftly followed
by the US Food and Drug Administration. Reversible antiplatelet
agents acting as P2Y12 antagonists similar to ticagrelor are cangrelor,
and elinogrel. A new class of oral protease-activated receptor-1
(PAR-1) inhibitors, vorapaxar and atopaxar has also been proposed
as effective antiplatelets but their clinical beneﬁt is still under
debate. The P2Y12 antagonists prasugrel and ticagrelor prevent
adverse cardiac outcomes albeit their absolute beneﬁt is very small.
The beneﬁcial effect of prasugrel and ticagrelor comes at a cost of an
increased risk of bleeding. Furthermore, new adverse effects have
also become evident with the new P2Y12 antagonists and these
include dyspnea (for all of the reversible P2Y12 antagonists:
ticagrelor, cangrelor, and elinogrel) and ventricular pauses for
ticagrelor. In addition, the newer P2Y12 antagonists have a peculiar
pharmacodynamic proﬁle with a fast onset and offset. Two of these
agents, cangrelor and elinogrel, are available as intravenous formu-
lations, which may provide additional beneﬁts in patients who
undergo coronary artery bypass graft (CABG) surgery. Trials with the
PAR-1 inhibitors have also shown trends toward reductions in
cardiac events, but not without the possibility of increased bleeding.
Physicians must carefully assess patient-speciﬁc factors such as risk
of thrombosis, concomitant disease states, age, drug adherence, and
aspirin dose, and plan for those patients who will be undergoing
CABG when selecting antiplatelet therapy in order to optimally
balance bleeding and thrombosis risk.
In addition to adequate anti-platelet therapy the treatment of
blood lipids is important for the primary and secondary prevention
of cardiovascular disease. Elevated low-density lipoprotein choles-
terol is an important risk factor for cardiovascular and cerebro-
vascular events. HMG-CoA reductase inhibitors, or statins, are very
effective in lowering cholesterol levels, and in reducing mortality and
cardiovascular events in patients with and without cardiovascular
disease. The evidence cumulated with the studies conducted with
statin has led to the recent recommendations that all patients with
known vascular disease, or who are at high risk for vascular disease,
should be considered candidates for statin therapy. Nonstatin
therapies (either as monotherapy or in addition to statins) to reduce
LDL cholesterol by mechanisms that do not involve inhibition of
HMG-CoA reductase are likely to be useful for patients in need of LDL
reduction; particularly those who either cannot take statins or
respond only partially or not at all to statins alone. These therapies
include cholesterol absorption inhibitors, Acyl-CoA cholesterol acyl
transferase inhibitors, farnesoid X receptor antagonists, sterol-
regulating binding protein cleavage activating protein, and micro-
somal triglyceride transfer protein. Recent studies with the PCSK9
have shown that these drugs signiﬁcantly reduce total and LDL
cholesterol in patients with familial hypercholesterolaemia and that
are effective in further reducing plasma cholesterol levels in patients
receiving statins.
Therefore, therapeutic options are becoming available for patients
who cannot tolerate full dose statin therapy or for those few patients
who are intolerant to statin therapy.
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Coronary artery disease is the leading cause of death in the
industrialised Countries and angina pectoris is a common symptom
of this disease. “Angina” is a term used to describe the clinical
symptoms that are induced by physical exertion or emotional stress
and subside with rest or treatment with sublingual nitrates. Some
patients, especially those with type II diabetes mellitus, do not
experience chest discomfort but complain of dyspnoea, breathless-
ness or tiredness. All those symptoms are related to myocardial
ischemia and are anginal equivalents.
The treatment of angina andmyocardial ischemia involves a number
of strategies. The ﬁrst step in angina management includes aggressive
control of risk factors, such as smoking, hypertension, dyslipidemia,
diabetes mellitus, obesity, and physical inactivity. While alterations in
these risk factors may improve symptoms and reduce cardiac events,
the majority of patients with chronic stable angina require speciﬁc
antianginal medications. Beta-adrenergic blocking drugs are recom-
mended as ﬁrst-line therapy for patients with angina. However the
cardioprotective effects of these drugs have been shown only in patients
with left ventricular dysfunction and post an acutemyocardial infarction.
Other therapies for chronic angina include calcium channel blocking
agents and nitrates, but such medical therapy often does not provide
adequate symptomatic relief. A number of novel therapies are directed at
angina treatment, including new pharmacologic agents, gene therapy,
enhanced external counterpulsation (EECP), spinal cord stimulation, and
innovations in revascularization therapy.
New pharmacologic agents. Metabolic modulators are a class of
drugs with a novel approach to the treatment of myocardial ischemia
and angina. During increased metabolic demands as well during
myocardial ischemia, glucose oxidation is a more efﬁcient way of
generating energy high-energy phosphates (ATP) than free fatty acid
oxidation. Unlike most current classes of anti-anginals, metabolic
modulators are effective without having haemodynamic effects and
therefore without affecting heart rate or blood pressure.
Trimetazidine, has demonstrated anti-ischemic effects in several
studies of patients with angina and in patients with heart failure.
Trimetazidine increases effort tolerance and delays the appearance of
ischemic symptoms and electrocardiographic (ECG) changes. In
addition, patient safety and tolerance with trimetazidine has been
good. The efﬁcacy of trimetazidine has also been demonstrated in
patients with diabetes, who showed improved exercise capacity and
duration after 4 weeks of treatment. Left ventricular dysfunction has
improved during therapy with trimetazidine.
Ranolazine is another metabolic agent that inhibits free fatty acid
oxidation and blocks the myocardium inward late sodium currents
thereby limiting the accumulation of intracellular calcium and reducing
the cellular energy expenditure. Ranolazine has been shown to improve
exercise induced myocardial ischemia alone and in association with
other anti-anginal drugs. Furthermore, Ranolazine has anti-arrhythmic
properties that have been shown in patients with acute coronary
syndromes and in patients with stable coronary artery disease. Currently
studies are underway to elucidate a potential use of Ranolazine in
patients with atrial ﬁbrillation.
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